New York, NY (PRWEB) December 01, 2022 The Conference Forum announced Carolyn R Bertozzi, PhD, Stanford University, 2022 Nobel Prize Winner in Chemistry,
IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM’s clinical pipeline of proprietary IgM antibodies. He joins IGM with 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences, Inc. Daniel S. Chen, M.D., Ph.D., will continue to assist the Company in a consulting capacity.
Society for Immunotherapy of Cancer to Host Back-to-Back Workshops on Tumor Cell Surfaceome and Bispecific T cell Engagers
Share Article
The Society for Immunotherapy of Cancer (SITC) will host two timely, back-to-back workshops Sept. 29–Oct. 1, 2021, in San Diego which will address critical challenges, facilitate innovative collaborations, and develop strategies to ensure continued momentum in drug development in the field of cancer immunotherapy.
Society for Immunotherapy of Cancer
“SITC is continually developing educational and networking opportunities to create a lasting impact on clinical practice by highlighting emerging topics relevant to immuno-oncology,” said SITC President Patrick Hwu, MD. MILWAUKEE (PRWEB) April 07, 2021 The Society for Immunotherapy of Cancer (SITC) will host two timely, back-to-back workshops Sept. 29–Oct. 1, 2021, in San Diego which will address critical challenges, faci